A Single-center, Single-arm, Open-label, Exploratory Study Evaluating Fruquintinib Combined With Sintilimab in Second-line Treatment of Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Latest Information Update: 20 Sep 2024
At a glance
- Drugs Fruquintinib (Primary) ; Sintilimab (Primary)
- Indications Adenocarcinoma; Gastric cancer; HER2 negative breast cancer; Oesophageal cancer
- Focus Therapeutic Use
- 13 Sep 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 13 Sep 2024 Status changed from not yet recruiting to active, no longer recruiting.
- 20 Jan 2024 According to Results presented at the 2024 Gastrointestinal Cancers Symposium, an optimal Simon two-stage design was employed: if more than 1 pt achieved objective responses in the first stage (n = 7), the study would proceed to the second stage and enroll an additional 19 pts; otherwise, the study would be terminated.